帕博利珠单抗对比伊匹木单抗治疗晚期黑色素瘤的5年随访结果
该结果进一步支持帕博利珠单抗在晚期黑色素瘤中的应用。
要点
- 3-4级治疗相关不良事件发生率帕博利珠单抗组17%,伊匹木单抗组20%。
核心结论
- 经过近5年随访,帕博利珠单抗对比伊匹木单抗在晚期黑色素瘤中持续显示优越性。
研究设计与样本
- KEYNOTE-006是一项开放标签、多中心、随机、对照的3期研究,在16个国家的87个学术机构、医院和癌症中心进行。
- 共入组834例年龄≥18岁、ECOG PS 0-1、未接受过伊匹木单抗、组织学确诊的晚期黑色素瘤患者,已知BRAF V600状态且既往系统治疗不超过1线。
- 患者按1:1:1随机分配至帕博利珠单抗10 mg/kg每2周组(n=279)、每3周组(n=277)或伊匹木单抗3 mg/kg每3周共4次组(n=278)。
- 帕博利珠单抗治疗持续最多24个月;符合条件的患者可在疾病进展后接受额外17个周期的帕博利珠单抗治疗。
主要发现
- 3-4级治疗相关不良事件在帕博利珠单抗联合组555例中发生96例(17%),伊匹木单抗组256例中发生50例(20%);最常见为结肠炎(11例[2%] vs 16例[6%])、腹泻(10例[2%] vs 7例[3%])和乏力(4例[<1%] vs 3例[1%])。
- 任何级别的严重治疗相关不良事件在帕博利珠单抗联合组发生75例(14%),伊匹木单抗组发生45例(18%)。
- 帕博利珠单抗组有1例患者死于治疗相关脓毒症。
临床怎么用
- 长期随访数据支持帕博利珠单抗作为晚期黑色素瘤的一线标准治疗。
- 帕博利珠单抗的生存获益在近5年随访中持续优于伊匹木单抗,且3-4级不良事件发生率较低。
局限性
- 本分析为事后探索性分析,非 protocol 预设。
- 帕博利珠单抗两种给药方案组的合并分析非 protocol 预设。
- 5年随访的疗效和安全性评估为探索性,未在 protocol 中指定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pembrolizumab improved progression-free survival and overall survival versus ipilimumab in patients with advanced melanoma and is now a standard of care in the first-line setting. However, the optimal duration of anti-PD-1 administration is unknown. We present results from 5 years of follow-up of patients in KEYNOTE-006. METHODS: KEYNOTE-006 was an open-label, multicentre, randomised, controlled, phase 3 study done at 87 academic institutions, hospitals, and cancer centres in 16 countries. Patients aged at least 18 years with Eastern Cooperative Oncology Group performance status of 0 or 1, ipilimumab-naive histologically confirmed advanced melanoma with known BRAFV600 status and up to one previous systemic therapy were randomly assigned (1:1:1) to intravenous pembrolizumab 10 mg/kg every 2 weeks or every 3 weeks or four doses of intravenous ipilimumab 3 mg/kg every 3 weeks. Treatments were assigned using a centralised, computer-generated allocation schedule with blocked randomisation within strata. Exploratory combination of data from the two pembrolizumab dosing regimen groups was not protocol-specified. Pembrolizumab treatment continued for up to 24 months. Eligible patients who discontinued pembrolizumab with stable disease or better after receiving at least 24 months of pembrolizumab or discontinued with complete response after at least 6 months of pembrolizumab and then progressed could receive an additional 17 cycles of pembrolizumab. Co-primary endpoints were overall survival and progression-free survival. Efficacy was analysed in all randomly assigned patients, and safety was analysed in all randomly assigned patients who received at least one dose of study treatment. Exploratory assessment of efficacy and safety at 5 years' follow-up was not specified in the protocol. Data cutoff for this analysis was Dec 3, 2018. Recruitment is closed; the study is ongoing. This study is registered with ClinicalTrials.gov, number NCT01866319. FINDINGS: Between Sept 18, 2013, and March 3, 2014, 834 patients were enrolled and randomly assigned to receive pembrolizumab (every 2 weeks, n=279; every 3 weeks, n=277), or ipilimumab (n=278). After a median follow-up of 57·7 months (IQR 56·7-59·2) in surviving patients, median overall survival was 32·7 months (95% CI 24·5-41·6) in the combined pembrolizumab groups and 15·9 months (13·3-22·0) in the ipilimumab group (hazard ratio [HR] 0·73, 95% CI 0·61-0·88, p=0·00049). Median progression-free survival was 8·4 months (95% CI 6·6-11·3) in the combined pembrolizumab groups versus 3·4 months (2·9-4·2) in the ipilimumab group (HR 0·57, 95% CI 0·48-0·67, p<0·0001). Grade 3-4 treatment-related adverse events occurred in 96 (17%) of 555 patients in the combined pembrolizumab groups and in 50 (20%) of 256 patients in the ipilimumab group; the most common of these events were colitis (11 [2%] vs 16 [6%]), diarrhoea (ten [2%] vs seven [3%]), and fatigue (four [<1%] vs three [1%]). Any-grade serious treatment-related adverse events occurred in 75 (14%) patients in the combined pembrolizumab groups and in 45 (18%) patients in the ipilimumab group. One patient assigned to pembrolizumab died from treatment-related sepsis. INTERPRETATION: Pembrolizumab continued to show superiority over ipilimumab after almost 5 years of follow-up. These results provide further support for use of pembrolizumab in patients with advanced melanoma. FUNDING: Merck Sharp & Dohme.
引用
- Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019. PMID: 31345627. doi:10.1016/S1470-2045(19)30388-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。